Dataset Information

A comparison of the geographic patterns of HIV prevalence and hurricane events in the United States.

ABSTRACT: OBJECTIVES:Previous research has documented the adverse association between hurricanes and HIV health outcomes; however, no research has been conducted to examine whether there is spatial overlap between hurricane events and the epidemiology of HIV in the United States. The objectives of this study were to assess the geographic distributions of and spatial autocorrelation between HIV prevalence and the occurrences of hurricanes in the US. STUDY DESIGN:This was a cross-sectional study. METHODS:Data on HIV prevalence rates were obtained from the Centers for Disease Control and Prevention, and data on US hurricane events were obtained from the National Oceanic and Atmospheric Administration. ArcGIS, version 10.6, was used for mapping HIV prevalence rates and occurrences of hurricane events, and GeoDa, version 1.12, was used to conduct all univariate and bivariate spatial autocorrelation analyses. RESULTS:HIV and hurricanes primarily affected states located in the south and along the Gulf Coast. Major hurricanes were reported among these regions also. States recording 20 or more hurricanes between 1851 and 2017 had an average HIV prevalence rate of 453.2 cases per 100,000 in 2016. States recording five or more major hurricanes between 1851 and 2017 had an average HIV prevalence rate of 421.8 cases per 100,000 in 2016. Regarding univariate spatial autocorrelation, HIV prevalence was clustered (Moran's I: 0.1913; pseudo P-value: 0.003). Hurricane events were also clustered (Moran's I: 0.2826; pseudo P-value: 0.004), as were major hurricanes (Moran's I: 0.1982; pseudo P-value: 0.009). There was statistically significant bivariate spatial autocorrelation between neither HIV and hurricanes nor HIV and major hurricanes. CONCLUSION:The epidemiology of HIV prevalence and hurricane events has overlapping geographic patterns. This may have implications for hurricane readiness and recovery planning with respect to people living with HIV.

SUBMITTER: Danielle Sharpe J

PROVIDER: S-EPMC6579037 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A comparison of the geographic patterns of HIV prevalence and hurricane events in the United States.

Danielle Sharpe J J

Public health 20190523

<h4>Objectives</h4>Previous research has documented the adverse association between hurricanes and HIV health outcomes; however, no research has been conducted to examine whether there is spatial overlap between hurricane events and the epidemiology of HIV in the United States. The objectives of this study were to assess the geographic distributions of and spatial autocorrelation between HIV prevalence and the occurrences of hurricanes in the US.<h4>Study design</h4>This was a cross-sectional st ...[more]

PMID: 31129482

Similar Datasets

Project description:ImportanceHearing loss is one of the most prevalent chronic conditions in the United States and has been associated with negative physical, social, cognitive, economic, and emotional consequences. Despite the high prevalence of hearing loss, substantial gaps in the utilization of amplification options, including hearing aids and cochlear implants (CI), have been identified.ObjectiveTo investigate the contemporary prevalence, characteristics, and patterns of specialty referral, evaluation, and treatment of hearing difficulty among adults in the United States.Design, setting, and participantsA cross-sectional analysis of responses from a nationwide clustered representative sample of adults who participated in the 2014 National Health Interview Survey and responded to the hearing module questions was carried out.Main outcomes and measuresData regarding demographics as well as self-reported hearing status, functional hearing, laterality, onset, and primary cause of the hearing loss were collected. In addition, specific data regarding hearing-related clinician visits, hearing tests, referrals to hearing specialist, and utilization of hearing aids and CIs were analyzed.ResultsAmong 239.6 million adults, 40.3 million (16.8%) indicated their hearing was less than "excellent/good," ranging from "a little trouble hearing" to "deaf." The mean (SD) age of participants was 47 (0.2) years with 48.2% being men and 51.8% women. Approximately 48.8 million (20.6%) had visited a physician for hearing problems in the preceding 5 years. Of these, 32.6% were referred to an otolaryngologist and 27.3% were referred to an audiologist. Functional hearing was reported as the ability to hear "whispering" or "normal voice" (225.4 million; 95.5%), to "only hear shouting" (8.0 million; 3.4%), and "not appreciating shouting" (2.8 million; 1.1%). Among the last group, 5.3% were recommended to have a CI, of which 22.1% had received one. Of the adults who indicated their hearing from "a little trouble hearing" to being "deaf," 12.9 million (32.2%) had never seen a clinician for hearing problems and 11.1 million (28.0%) had never had their hearing tested.Conclusions and relevanceThere are considerable gaps between self-reported hearing loss and patients receiving medical evaluation and recommended treatments for hearing loss. Improved awareness regarding referrals to otolaryngologists and audiologists as well as auditory rehabilitative options among clinicians may improve hearing loss care.

Project description:ImportanceRisk of opioid use disorder, overdose, and death from prescription opioids increases as dosage, duration, and use of extended-release and long-acting formulations increase. States are well suited to respond to the opioid crisis through legislation, regulations, enforcement, surveillance, and other interventions.ObjectiveTo estimate temporal trends and geographic variations in 6 key opioid prescribing measures in 50 US states and the District of Columbia.Design, setting, and participantsPopulation-based cross-sectional analysis of opioid prescriptions filled nationwide at US retail pharmacies between January 1, 2006, and December 31, 2017. Data were obtained from the IQVIA Xponent database. All US residents who had an opioid prescription filled at a US retail pharmacy were included.Main outcomes and measuresPrimary outcomes were annual amount of opioids prescribed in morphine milligram equivalents (MME) per person; mean duration per prescription in days; and 4 separate prescribing rates-for prescriptions 3 or fewer days, those 30 days or longer, those with a high daily dosage (≥90 MME), and those with extended-release and long-acting formulations.ResultsBetween 2006 and 2017, an estimated 233.7 million opioid prescriptions were filled in retail pharmacies in the United States each year. For all states combined, 4 measures decreased: (1) mean (SD) amount of opioids prescribed (mean [SD] decrease, 12.8% [12.6%]) from 628.4 (178.0) to 543.4 (158.6) MME per person, a statistically significant decrease in 23 states; (2) high daily dosage (mean [SD] decrease, 53.1% [13.6%]) from 12.3 (3.4) to 5.6 (1.7) per 100 persons, a statistically significant decrease in 49 states; (3) short-term (≤3 days) duration (mean [SD] decrease, 43.1% [9.4%]) from 18.0 (5.4) to 10.0 (2.5) per 100 persons, a statistically significant decrease in 48 states; and (4) extended-release and long-acting formulations (mean [SD] decrease, 14.7% [13.7%]) from 7.2 (1.9) to 6.0 (1.7) per 100 persons, a statistically significant decrease in 27 states. Two measures increased, each associated with the duration of prescription dispensed: (1) mean (SD) prescription duration (mean [SD] increase, 37.6% [6.9%]) from 13.0 (1.2) to 17.9 (1.4) days, a statistically significant increase in every state; and (2) prescriptions for a term of 30 days or longer (mean [SD] increase, 37.7% [28.9%]) from 18.3 (7.7) to 24.9 (10.7) per 100 persons, a statistically significant increase in 39 states. Two- to 3-fold geographic differences were observed across states, measured by comparing the ratio of each state's 90th to 10th percentile for each measure.Conclusions and relevanceIn this study, across 12 years, the mean duration and prescribing rate for long-term prescriptions of opioids increased, whereas the amount of opioids prescribed per person and prescribing rate for high-dosage prescriptions, short-term prescriptions, and extended-release and long-acting formulations decreased. Some decreases were significant, but results were still high. Two- to 3-fold state variation in 5 measures occurred in most states. This information may help when state-specific intervention programs are being designed.

Project description:ImportanceAutism spectrum disorder (ASD) is a complex neurodevelopmental disorder. Previous surveys have reported a steady increase in ASD prevalence in US children over the past decades. Several behavioral therapies and medications have been developed to treat the symptoms of ASD; however, little is known about the current status of treatment usage for children diagnosed as having ASD.ObjectiveTo estimate the prevalence and treatment patterns of ASD among US children using nationally representative data.Design, setting, and participantsThis study used data from the 2016 National Survey of Children's Health, a nationwide, population-based, cross-sectional survey. We included 43 032 children aged 3 to 17 years. Data were collected through questionnaires completed by a parent or guardian. Data were analyzed from February 2018 to March 2018.Main outcomes and measuresOutcome variables included ASD diagnosed by a physician or health professional and the use of behavioral treatment or medication treatment among children with ASD.ResultsOf the 43 032 included participants, 22 072 (51.3%) were male, and the mean (SD) age was 10.7 (4.4) years. The weighted prevalence of ever-diagnosed ASD and current ASD were 2.79% (95% CI, 2.46-3.12) and 2.50% (95% CI, 2.21-2.79), respectively. The state-level prevalence of ever-diagnosed ASD varied from 1.54% (95% CI, 0.60-2.48) in Texas to 4.88% (95% CI, 2.72-7.05) in Florida. Nationally, about 70% of children with current ASD (70.5%; 95% CI, 65.1-75.8) were treated; 43.3% (95% CI, 37.4-49.2) received behavioral treatment only, 6.9% (95% CI, 3.7-10.1) received medication treatment only, and 20.3% (95% CI, 16.5-24.1) received both behavioral and medication treatments. The remaining 29.5% (95% CI, 24.2-34.9) of children with current ASD did not receive either behavioral or medication treatment.Conclusions and relevanceThis study showed that the prevalence of ASD in the United States was relatively high, and it varied substantially across US states. Almost 30% of US children with ASD did not receive behavioral or medication treatment, which calls for a critical need to understand and address the barriers for those children to receive appropriate treatments.

Dataset Information

A comparison of the geographic patterns of HIV prevalence and hurricane events in the United States.

Publications

A comparison of the geographic patterns of HIV prevalence and hurricane events in the United States.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets